Aberdeen Group plc Sells 40,917 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Aberdeen Group plc reduced its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 60.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,740 shares of the company’s stock after selling 40,917 shares during the period. Aberdeen Group plc’s holdings in Rhythm Pharmaceuticals were worth $2,700,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Advisors Asset Management Inc. lifted its stake in Rhythm Pharmaceuticals by 4.3% during the third quarter. Advisors Asset Management Inc. now owns 14,178 shares of the company’s stock worth $1,432,000 after purchasing an additional 582 shares during the period. Profund Advisors LLC raised its holdings in shares of Rhythm Pharmaceuticals by 10.7% in the 3rd quarter. Profund Advisors LLC now owns 12,457 shares of the company’s stock worth $1,258,000 after buying an additional 1,203 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after buying an additional 141 shares during the period. Penserra Capital Management LLC acquired a new stake in Rhythm Pharmaceuticals in the 3rd quarter valued at $3,073,000. Finally, WCM Investment Management LLC acquired a new stake in Rhythm Pharmaceuticals in the 3rd quarter valued at $4,804,000.

Insiders Place Their Bets

In other news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares of the company’s stock, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at $11,190,445.12. This trade represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,003 shares of company stock worth $2,589,015 over the last quarter. Corporate insiders own 6.10% of the company’s stock.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC/ Royal Bank initiated coverage and/or upgraded RYTM with an outperform/moderate-buy stance, bringing renewed institutional attention and a formal buy-style endorsement that can support near-term demand. RBC initiates coverage
• Positive Sentiment: Several sell-side firms have raised price targets and reiterated buy/overweight ratings (Wells Fargo, Morgan Stanley, Citizens/JMP, UBS, TD Cowen), reinforcing a bullish consensus and higher upside expectations. MarketBeat analyst roundup
• Positive Sentiment: Operational narrative improving: a Yahoo Finance piece highlights Imcivree revenue ramp and updated management targets — if execution continues, this supports medium-term revenue growth that underpins analyst optimism. Imcivree revenue and targets
• Neutral Sentiment: Zacks moved coverage from “strong sell” to “hold” and flagged RYTM as positioned to potentially beat upcoming earnings — these are watchpoints that reduce perceived downside but are not immediate catalysts without reported results. Zacks coverage and earnings outlook
• Negative Sentiment: Insider selling by CFO Hunter C. Smith: filings show sales of several thousand shares (transactions reported for Feb. 17 and Feb. 19 at ~ $101 per share). While the amounts are a small percentage of his total holding, such sales can trigger near-term selling pressure or investor concern about insider conviction. CFO sale disclosure

Rhythm Pharmaceuticals Trading Down 3.3%

Shares of NASDAQ RYTM opened at $99.78 on Friday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $45.90 and a 1-year high of $122.20. The company has a 50-day moving average of $105.41 and a two-hundred day moving average of $103.40. The company has a market cap of $6.66 billion, a PE ratio of -32.19 and a beta of 2.00.

Wall Street Analysts Forecast Growth

RYTM has been the subject of several recent analyst reports. Guggenheim increased their price objective on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Citigroup reiterated an “outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Friday, December 12th. UBS Group reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, December 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $150.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Finally, Wall Street Zen cut shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.50.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.